Continuum Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$330K Sell
665
-20
-3% -$8.86K 0.03% 374
2026
Q1
$306K Sell
685
-947
-58% -$442K 0.03% 362
2025
Q4
$740K Buy
1,632
+86
+6% +$37.1K 0.07% 230
2025
Q3
$605K Sell
1,546
-193
-11% -$80.7K 0.06% 250
2025
Q2
$774K Buy
1,739
+74
+4% +$34.1K 0.09% 202
2025
Q1
$807K Buy
1,665
+89
+6% +$41.5K 0.1% 171
2024
Q4
$635K Buy
1,576
+11
+0.7% +$5.1K 0.08% 213
2024
Q3
$757K Sell
1,565
-116
-7% -$55.7K 0.1% 193
2024
Q2
$788K Buy
1,681
+71
+4% +$30.8K 0.11% 179
2024
Q1
$675K Buy
1,610
+269
+20% +$114K 0.1% 197
2023
Q4
$547K Buy
1,341
+81
+6% +$29.9K 0.08% 267
2023
Q3
$438K Buy
1,260
+95
+8% +$33.2K 0.07% 297
2023
Q2
$410K Sell
1,165
-42
-3% -$14.2K 0.07% 317
2023
Q1
$380K Buy
1,207
+425
+54% +$127K 0.06% 305
2022
Q4
$226K Sell
782
-26
-3% -$7.92K 0.04% 385
2022
Q3
$234K Buy
+808
New +$232K 0.04% 359

Other funds holding VRTX

Continuum Advisory's VRTX Position: Q2 2026 in Review

Continuum Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q2 2026, selling an estimated $8.86K and leaving 665 shares worth $330K. The position accounts for 0.03% of the portfolio, ranked #374.

Continuum Advisory first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $807K in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Continuum Advisory held 665 shares of Vertex Pharmaceuticals worth $330K as of Q2 2026.
  • Continuum Advisory sold 20 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.86K.
  • Vertex Pharmaceuticals made up 0.03% of Continuum Advisory's portfolio in Q2 2026, its #374 holding.
  • Continuum Advisory first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Continuum Advisory's Vertex Pharmaceuticals position peaked at $807K in Q1 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.